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Known human immunodeficiency virus (HIV) transmission histories are invaluable models for investigating
the evolutionary and transmission dynamics of the virus and to assess the accuracy of phylogenetic recon-
structions. Here we have characterized an HIV-1 transmission chain consisting of nine infected patients,
almost all of whom were treated with antiviral drugs at later stages of infection. Partial pol and env gp41 regions
of the HIV genome were directly sequenced from plasma viral RNA for at least one sample from each patient.
Phylogenetic analyses in pol using likelihood methods inferred an evolutionary history not fully compatible
with the known transmission history. This could be attributed to parallel evolution of drug resistance muta-
tions resulting in the incorrect clustering of multidrug-resistant virus. On the other hand, a fully compatible
phylogenetic tree was reconstructed from the env sequences. We were able to identify and quantify the
molecular footprint of drug-selective pressure in pol using maximum likelihood inference under different codon
substitution models. An increased fixation rate of mutations in the HIV population of the multidrug-resistant
patient was demonstrated using molecular clock modeling. We show that molecular evolutionary analyses,
guided by a known transmission history, can reveal the presence of confounding factors like natural selection
and caution should be taken when accurate descriptions of HIV evolution are required.
The evolution of human immunodeficiency virus (HIV)
within and across hosts is known to be remarkably different
(11, 31). Within hosts, the viral population is subjected to
natural selection as a result of a continuous effort to evade the
immune response. This process is frequently reflected in tem-
poral phylogenetic structures showing the continual appear-
ance and extinction of strains through time (11, 34). Across
hosts, positive selective pressure does not seem to have an
important impact. Instead, HIV genetic diversity is predomi-
nately shaped by spatial and temporal factors in the demo-
graphic history (11, 31). Understanding how intrahost evolu-
tion translates into HIV evolution at the population level is a
key factor in determining how drug resistance and immune
escape mutations might spread. Treating HIV-1-infected pa-
tients with highly active antiretroviral therapy (HAART) has
led to a remarkable reduction in HIV-related morbidity and
mortality (28). However, no antiretroviral is resistance proof,
and when HIV replication is not fully suppressed, drug resis-
tance inevitably appears. In countries where antiretrovirals are
widely used, growing concern exists about the transmission of
resistant viruses. Many efforts are currently being undertaken
to monitor and control its spread. Accurately tracking HIV
transmission in the population can provide useful data to in-
vestigate this issue. Only recently, an HIV transmission chain
provided the proof of principle for transmission of drug resis-
tance (38).
Well-characterized HIV transmission chains are much ap-
preciated in a phylogenetic context. Assuming that the viral
phylogeny should be consistent with the “true” transmission
history, transmission chains allow assessment of the accuracy
and reliability of phylogenetic reconstructions (19). Unlike
simulation studies, which cannot fully capture the biological
complexity of HIV evolution, transmission chains are informa-
tive on the performance of methods for real data. One of the
most carefully studied examples involves a Swedish HIV-1
transmission chain consisting of nine individuals from whom 13
samples were obtained (19). Using sequences sampled in the
gag and env genes, several tree reconstruction methods were
tested for their ability to reconstruct the true transmission
history. Except for one mother-to-child transmission event, the
viral tree, reconstructed using maximum likelihood methods
and realistic nucleotide substitution models, agreed with the
known transmission history (19, 21). In addition, molecular
clock analysis revealed that genetic divergence correlated well
with the isolation dates of the samples and that significant
genetic divergence, referred to as ancestral divergence, existed
between the donor and recipient lineage at the time of trans-
mission (17).
Although the characterization of a transmission chain of this
scope—in terms of patients involved, separation times between
samples, and sequence data obtained—is unique in the epi-
demic history of HIV, it has been taken as a strong argument
for the accuracy of phylogenetic reconstructions (10, 19, 20). It
remains, however, uncertain how robust evolutionary analyses
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are with respect to biological complications, like recombina-
tion and natural selection. Unfortunately, known transmission
chains allowing us to address these issues are rare. Here, we
present an HIV transmission cluster consisting of nine infected
patients for whom the time and direction of each virus trans-
mission were determined by in-depth patient interviews. Re-
constructed phylogenies based on pol and env gp41 gene se-
quences were evaluated for their compatibility with the known
transmission history. A particular clustering in the pol tree,
topologically incongruent with the transmission history, is at-
tributed to drug-selective pressure in a multidrug-resistant pa-
tient. Natural selection in the HIV transmission chain, and in
the multidrug-resistant patient in particular, was investigated
using codon substitution models; the impact on the evolution-
ary rate is demonstrated using molecular clock modeling.
MATERIALS AND METHODS
Study population. The epidemiological relationships between nine HIV-1-
infected patients attending the University Hospitals Leuven were established
through in-depth interviews by physicians experienced in HIV care. A time
interval for each transmission event was determined by the following contact
tracing criteria (if available): (i) the patient reporting a high-risk contact, (ii) the
patient’s most recent negative HIV test, and (iii) a history of an acute viral
syndrome (which indicates an infection in the range of several days up to 10
weeks in the past). Each patient provided written informed consent, and at least
one blood sample was obtained between 1990 and 2002. Epidemiologically un-
related control sequences, having the same subtype as the strains constituting the
transmission chain, were obtained from a local database (local controls) and
from GenBank using BLAST (2). Control sequences with drug resistance mu-
tations were retrieved from the HIV Drug Resistance Database (http://hivdb
.stanford.edu/).
RNA extraction, cDNA synthesis, amplification, and sequencing of the pol and
env region. Plasma was isolated from the blood sample, and HIV RNA was
extracted using a QIAamp Viral RNA Mini kit (Westburg, Leusden, The Neth-
erlands). cDNA synthesis and PCR amplification of the pol gene region were
performed using an in-house protocol (40). env gp41 cDNA synthesis and PCR
amplification were performed as previously described (41). Direct sequencing of
the purified nested PCR products was performed using the ABI PRISM BigDye
Terminator v3.1 Ready Reaction Cycle Sequencing kit and analyzed on the
ABI3100 genetic analyzer (Applera, Nieuwerkerk a/d Ijssel, The Netherlands).
Sequence fragments of 1,069 bp for pol and 951 bp for env were assembled and
analyzed using Sequence Analysis version 3.7 and SeqScape version 2.0 (Ap-
plera, Nieuwerkerk a/d Ijssel, The Netherlands).
Phylogenetic inference. Sequences were aligned using CLUSTAL X (39) and
manually edited according to their codon-reading frame in Se-Al (http://evolve
.zoo.ox.ac.uk). Regions that could not be unambiguously aligned in the env gp41
gene were deleted from the alignment. For a representation of the pol alignment,
see the supplemental material. Hypermutation and recombination were investi-
gated using Hypermut and Simplot v2.5, respectively (22, 33). Appropriate nu-
cleotide substitution models were determined with Modeltest v3.06 (29). Maxi-
mum likelihood phylogenetic trees were reconstructed in PAUP* (v4b10) using
three different heuristic branch-swapping algorithms (37). Bootstrapping was
performed using the stepwise addition algorithm for 1,000 replicates. Maximum
a posteriori trees were inferred using MrBayes (v3.0) (13). Synonymous and
FIG. 1. Real-time HIV-1 transmission history as identified by contact tracing. The open arrows denote the transmission events; the width of
the arrows represents the time interval for transmission. The arrow representing the transmission event between patient A and patient B is dashed
because the time and direction of transmission could not be determined. The patient’s bars filled with gray indicate an HIV-1-infected status with
(superimposed) the therapy history. The therapy history is either monotherapy (Mono), bitherapy (Bi), or HAART. †, patient is deceased. The
bent black arrows indicate available samples, including date of isolation.
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nonsynonymous trees were reconstructed using the neighbor-joining method
based on distance matrices estimated in Syn-Scan, which uses a model that
includes allelic mixtures (8). Different tree topologies were compared using the
Kishino-Hasegawa test and the Shimodaira-Hasegawa test (16, 36).
Molecular adaptation at individual sites (26, 44), along specific lineages (45),
and at individual sites along specific lineages (43) was investigated using codon
substitution models as implemented in PAML (v3.13) (42). To test for diversi-
fying selection at individual sites, different models were compared that allow for
heterogeneous nonsynonymous/synonymous substitution rate ratios (  dN/dS)
among sites (models M0, M1, M2, M3, M7, and M8; see reference 44). Likeli-
hood ratio testing (LRT) was used to test whether allowing for sites with   1
significantly improves the fit of the model to data (M1-M2, M0-M3, and M7-M8,
where M2, M3, M7 can accommodate positively selected sites). To investigate
different selective pressure along specific lineages, we tested a model that allows
only a single  for all branches in the tree (M0) against a two-ratio model that
allows an additional  for specific branches in the tree. Positively selected sites
along the lineages of interest were identified using branch site models (43).
Branch site model A is an extension of the neutral model (M1) because it allows
for sites being positively selected along a prespecified lineage while belonging to
the class with 0  0 or 1  1 in the background. In branch site model B, 0
and 1 are estimated as free parameters, and thus it is an extension of the
discrete model (M3 with two discrete classes of sites).
Molecular clock analysis was performed using maximum likelihood methods
implemented in PAML (v3.13b) (42). Evolutionary rates were estimated under
the assumption of a constant rate of evolution for sequences that were serially
sampled over time (single rate dated tip model [SRDT]) (30). The molecular
clock was tested by comparing the SRDT model against an unconstrained dif-
ferent rates (DR) model using LRT (30).
Nucleotide sequence accession number. The sequences described here have
been submitted to the GenBank database and assigned accession numbers
AF338984, AF338990, AF338992, AF338997, AF339013, AF339017, and
AY749169 to AY749196 for the pol sequences and AY749197 to AY749208 for
the env gp41 sequences.
RESULTS
The known transmission history. In this study, we identified
a heterosexual HIV-1 transmission chain consisting of nine
individuals. The epidemiological information obtained by pa-
tient interviews and the clinical data, the time of sampling and
the treatment history of the patients are summarized in Fig. 1.
The direction of transmission and a relatively narrow time
interval were determined for all transmission events, with the
exception of patients A and B. Although there was clearly a
transmission event between both patients, they reported each
other as the original donor and a time interval could not be
defined. Since several viral phylogenies might have resulted
from this transmission history, we did not attempt to recon-
struct a single known phylogenetic tree. Instead, the scheme of
the “true” transmission history was considered as a pathway
along which the viral population is assumed to have evolved.
We have further used the term “compatible” if the viral phy-
logeny could have been generated under the known transmis-
sion history. Similar to the Swedish transmission chain (19),
this transmission history spans more than a decade of HIV-1
evolution; however, the transmission chain reported here is
situated almost exactly one decade later than the Swedish
transmission chain. Reflecting the progress of HIV research
and treatment during this decade, almost all patients of our
transmission chain have received antiretroviral therapy. We
chose to obtain sequence data for the relatively conserved pol
gene region, which is used to test for resistance against com-
monly available drugs, and the more variable env gp41 gene
region, which is anticipated to be used for testing resistance
against fusion inhibitors (41).
The viral evolutionary history. In a first analysis, we tested
whether the sequences obtained from the transmission chain
patients were more closely related to each other than to unre-
lated control sequences. This represents the general hypothesis
test for molecular investigations in forensic settings (5, 18, 25,
27). Phylogenetic analysis of 16 pol sequences from the nine
transmission chain patients, as well as a set of unrelated con-
trols extracted from a local database and GenBank, confirmed
with statistical significance that the transmission chain se-
quences constituted a monophyletic cluster in the subtype C
phylogeny (Fig. 2). A similar analysis of the reverse transcrip-
tase (RT) gene, including additional control sequences with
matched drug resistance mutations, still identified the trans-
mission chain as a monophyletic cluster (see the supplemental
material). To test if the evolutionary history of the virus was
compatible with the known transmission history, molecular
FIG. 2. Maximum likelihood phylogenetic reconstruction for the
HIV-1 transmission chain patients and unrelated controls based on the
pol gene region. The sequences sampled from the transmission chain
patients are represented in bold. Subtype C sequences retrieved from
a local database are labeled “LC.” The tree is rooted at its midpoint.
The upper numbers at the nodes indicate the percentage of neighbor-
joining bootstrap samples, based on 1,000 replicates, in which the node
is supported (only values of 80% are shown). The lower numbers at
the nodes represent approximate posterior probabilities obtained from
a posterior sample of trees (only values of 80% are shown).
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phylogenies were reconstructed based on pol and env gp41
sequences. Maximum likelihood reconstructions based on both
gene regions are depicted in Fig. 3. Both maximum likelihood
and Bayesian inference resulted in the exact same topologies.
In Fig. 3, the most likely host transmission history is superim-
posed onto the viral tree, indicating that the evolutionary his-
tory in env gp41 was perfectly compatible with the known
transmission history, while the pol tree revealed a particular
incompatibility. According to the known transmission history,
the sequences for patients A, F, and G were expected to be
monophyletic, as correctly inferred in the env gp41 tree. How-
ever, the pol phylogeny did not suggest patient A as the donor
for F. As indicated in Fig. 3, this inconsistency could be re-
solved by a single branch swapping of (A00pop, A96pop) or
(F02pop, G02pop) in either direction. It is interesting to note
that the ML bootstrap support for the nodes relevant to the
incompatible tree was weak compared to the posterior proba-
bilities, suggesting that the more conservative bootstraps might
be less misleading in this case. Phylogenetic reconstruction
based on the concatenated pol and env gp41 alignment resulted
in the same topology as inferred for the env gp41 gene only.
For consistency, we have further referred to this topology as
the env gp41 tree. Using the Kishino-Hasegawa test and the
Shimodaira-Hasegawa test, we compared the env gp41 tree
topology, congruent with the known transmission history, with
the pol tree (Table 1). Although the pol reconstruction yielded
a better likelihood for the pol alignment, the env gp41 recon-
struction could not be significantly rejected by any test inde-
pendent of the evolutionary model used. For the env gp41 data,
however, the pol tree, not fully compatible with the known
transmission history, gave a significantly worse fit than the env
gp41 tree.
To investigate whether the unexpected clustering for the pol
gene could have resulted from drug-selective pressure, we
identified the drug resistance mutations for all samples based
on the mutation list available from the International AIDS
FIG. 3. Phylogenetic trees inferred for the pol and env gp41 gene regions. Maximum likelihood and Bayesian methods resulted in the same
topology for each gene region. Both trees are represented on the same scale and rooted at the position that does not distinguish between patient
A and patient B as the original donor for this transmission chain. The most likely host transmission scheme is superimposed onto the viral
evolutionary history: hosts are separated arbitrarily along the branch between donor and recipient. For isolates C99pop, D99pop, and I99pop320,
not enough sample was left to perform env gp41 sequencing. The upper numbers at the nodes indicate the percentage of bootstrap samples, based
on 1,000 replicates, in which the node is supported. The lower numbers at the nodes represent approximate posterior probabilities obtained from
a posterior sample of trees. The arrow in gray indicates the branch swapping that would make the pol phylogeny topologically congruent with the
known transmission history. The branch set tested to be under positive selective pressure is indicated in gray in the env gp41 tree; the branch tested
to have a higher nucleotide substitution rate is indicated with the horizontal bracket.
TABLE 1. P values for the tree incongruence tests
Dataa
P value for treeb:
pol env gp41
KH SH KH SH
pol Best ML tree Best ML tree 0.324 0.166
env gp41 0.001 0.001 Best ML tree Best ML tree
polenv 0.033 0.024 Best ML tree Best ML tree
pol-RT 0.822 0.388 Best ML tree Best ML tree
a polenv represents the concatenated pol and env gp41 alignment, and pol-RT
represents the pol alignment after exclusion of the positions associated with drug
resistance in the RT.
b The results for the Kishino-Hasegawa (KH) and Shimodaira-Hasegawa (SH)
tests are listed for the Hasegawa-Kishino-Yano model of evolution with gamma-
distributed rate heterogeneity among sites; the tests for other models of evolu-
tion are consistent with these results (data not shown).
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Society (Table 2) (14). Except for some natural polymor-
phisms, there was no evidence that resistance mutations were
transmitted in this transmission chain. The table reveals that
the virus in patient A had a significant number of resistance
mutations, and at the second time of sampling, this patient was
classified as multidrug resistant under ongoing exposure to
therapy. Since such amino acid-altering mutations might have
caused an incompatible phylogeny in pol, we reconstructed
trees for pol based on synonymous (silent) and nonsynonymous
(amino acid altering) distances separately (Fig. 4). While the
synonymous tree was now fully compatible with the known
transmission history, the nonsynonymous tree showed again
that the sequences from patient A did not cluster with F and G.
Instead, the patient A virus clustered with the patient I virus,
which had developed resistance mutations that were also all
present in the patient A virus (Table 2). Therefore, we could
argue that drug-selective pressure had resulted in a pattern of
parallel evolution. After exclusion of the codon positions in the
RT at which resistance mutations were identified, a pol phy-
logeny fully compatible with the known transmission history
could also be inferred (data not shown). For these data, which
contained only 10 codon sites less than the original pol align-
ment, the tree incongruence test results were inverted (Table
1). The env gp41 topology resulted now in a higher likelihood
than the original pol topology, but the latter was again not
significantly rejected. Comparison of the pol and env gp41
phylogenies also indicated that different tree topologies could
be compatible with the same transmission history. For exam-
ple, the patient H strain clustered with the patient I strain in
pol while the former clustered with a patient B isolate in env
gp41; however, both scenarios were compatible with the known
transmission history. In contrast to the pol tree, the tree topol-
ogy reconstructed for env gp41 based on nonsynonymous dis-
tances was compatible with the known transmission history
(data not shown).
Testing for selective pressure. Since we have identified a
topological incompatibility in the pol reconstruction and attrib-
uted it to drug-selective pressure, we could test whether this
has left a footprint of positive selection in the viral lineages of
interest. The nonsynonymous/synonymous substitution rate ra-
tio (  dN/dS) provides a qualitative measure of natural
selection at the protein level, with   1,   1, and   1,
indicating neutral evolution, purifying selection, and positive
selection, respectively. Since an averaging approach failed to
detect positive selection in a similar case of parallel evolution
under drug-selective pressure (4), we used more sensitive
codon substitution models to identify positive selection at in-
dividual sites (26, 44), along specific lineages (45), and at in-
dividual sites along specific lineages (43). As genealogy, we
used the tree reconstructed in the env gp41 gene (or pol plus
env gp41 concatenated alignment), which was consistent with
the transmission history (Fig. 3). The results of the maximum
likelihood inference under these models are summarized in
Table 3. The two-ratio model that allowed for a different  for
the patient A branches (ˆ1) compared to all other branches
(ˆ0) fitted significantly better than the one-ratio model (M0)
(P  0.0001). Although this provided evidence for a different
selective pressure in the patient A lineages, the  estimate for
these lineages (ˆ1  1.6230) was not significantly higher than
1 (P  0.3078).
The results of the site-specific models indicated that the
selective pressure on the protein varied greatly among amino
acid sites (Table 3). All models allowing for positively selected
sites (M2, M3, and M8) provided a significantly better fit to the
data than their neutral counterparts (M1, M0, and M7, respec-
tively). Interestingly, the positively selected sites identified by
the empirical Bayes’ criterion included several drug resistance-
associated mutations, mostly observed in more than one pa-
tient.
We further tested for sites under positive selection along the
lineage of interest using branch site models. Parameter esti-
mates under model A suggested that 65% of sites were highly
conserved across all lineages, with 0  0, and 18% of sites
were nearly neutral with 1 1, whereas the additional 17% of
sites were under strong positive selection along the patient A
branches, with ˆ2  4.74. In comparison with the simpler
neutral model (M1), model A showed a statistically significant
improvement (P  0.0045). Parameter estimates under model
B suggested that 4.7% of sites were under positive selection in
all lineages, with ˆ1  4.34, whereas 18% of sites were only
under positive selection in patient A, with ˆ2  2.91. The LRT
TABLE 2. Drug resistance-associated mutations
Patient and
sample
Pro
mutation(s)a RT mutation(s)
A
A96pop M36L M41L, D67DN, K70KR, L210LW, T215Y
A00pop L101, L33F, M41L, E44D, D67N, V118X, M184V,
M36L, G48V G190AG, L210W, T215HY, K219N,
154A, V82A F227FL
B
B90pop M36L
B96 M36L M41L, E44DE, V118IV, L2190W, T215Y
C
C94pop M36L
C99pop M36L
C02pop M36L
D
D99pop M36L
D01pop M36L
D02pop M36L
E
E01pop M36L V75IV
F
F02pop K20M, M36L
G
G02pop K20M, M36L
H
H98pop M36L M184V
I
I99pop320 M36L V118X, M184V, T215Y
I99pop506 M36L M184V, T215Y
a Drug resistance-associated mutations in protease (Pro) and RT were iden-
tified according to the criteria of the International AIDS Society—USA (14).
Protease mutations in bold represent major mutations. The ubiquitous M36L
mutation has been shown to confer cross-resistance to atazanavir in combination
with other known protease inhibitor resistance mutations, although it has not
been selected for by atazanavir either in vitro or in vivo (3). However, no patient
in this transmission chain has been treated with this drug. Also the K20M
mutation is only important in combination with other protease inhibitor resis-
tance mutations and should here be considered as natural polymorphism.
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indicated that the branch site model B was significantly better
than the site-specific model M3 (K  2) at the 0.05 confidence
level (P  0.025), suggesting positive selection in the patient A
lineages, in addition to positively selected sites in all lineages.
Interestingly, the positively selected sites identified for the
background included several positions at which drug resistance
mutations were identified in more than one patient (RT, 41,
184, 210, and 215) while the positively selected sites identified
for the foreground lineage included additional positions at
which drug resistance mutations were only found in patient A
(Pro, 10, 33, 48, 54, and 82; RT, 67 and 219). A similar analysis
of the env gp41 gene region also identified sites under positive
selection, but differential selective pressure in the specified
lineages was not observed (data not shown).
Molecular clock modeling. Our analyses indicated that sev-
eral mutations have been fixed under drug-selective pressure in
patient A, which could have resulted in a faster evolutionary
rate along this lineage. Exploratory linear regression analysis
appeared to confirm this effect in the terminal branch of taxon
A00pop (data not shown). To test this more formally, we
applied molecular clock modeling to the heterochronous se-
quence data. The results of the maximum likelihood inference
are shown in Table 4. The SRDT model, which constrains the
tips of the tree to be proportional to the sampling dates, re-
sulted in a nucleotide substitution rate of 0.00121 substitutions/
site/year. The single-rate model, which makes no accommoda-
tion for the temporal sampling of the isolates (30), was
significantly rejected by the LRT in favor of the SRDT model
(P  0.0001). This comparison suggested that incorporating
isolation dates into a single-rate model significantly improved
the likelihood. However, the SRDT model is rejected in favor
of the more general different rates (DR) model (P  0.0001),
indicating that the assumption of a global molecular clock was
violated. A local clock dated tips model, relaxing the molecular
clock along the branch leading to the taxon A00pop (Fig. 3),
fitted the data significantly better than the SRDT model (P 
0.0001). The rate estimated for the branch leading to the mul-
tidrug-resistant isolate was significantly higher than the back-
ground lineages (0.00616 substitutions/site/year; Table 4). It
should be noted that the local clock model was still significantly
rejected in favor of the DR model (P  0.0014). Also for the
env gp41 gene, a global molecular clock was rejected (DR
versus SRDT, P  0.0007), but no lineage effect in patient A
was observed (local clock dated tips versus SRDT, P  0.99).
DISCUSSION
In this study, we extensively documented a known HIV-1
transmission history almost a decade later than the Swedish
transmission chain (19). Although the number of people car-
rying HIV-1 is estimated to be around 40 million (www.unaids
.org), the long time span between the identification of both
transmission chains of comparable size reflects the rarity of
identifying such data. Sampling genetic data from known trans-
mission histories of fast-evolving pathogens provides the op-
portunity to investigate the accuracy of phylogenetic recon-
structions and the rate and mode at which genetic variation is
accumulated (17, 19, 21). Here, we have sequenced the pol and
env gp41 regions of the HIV-1 genome from plasma RNA in at
least one sample of nine infected patients. Phylogenetic recon-
structions using likelihood methods revealed that, in contrast
to the env gp41 tree, the pol tree was incompatible with the
known transmission history. The difference between transmis-
sion history and reconstructed topology in pol could be attrib-
uted to strong drug-selective pressure resulting in a pattern of
parallel evolution. Analysis of the pol data without the posi-
FIG. 4. Phylogenetic trees reconstructed using synonymous (dS) and nonsynonymous (dN) distances for pol. Both trees are represented as
rooted at the position that does not distinguish between patient A and patient B as the original donor for this transmission chain. The most likely
host transmission scheme is superimposed onto the viral evolutionary history. The arrow in gray indicates the branch swapping that would make
the dN phylogeny topologically congruent with the known transmission history.
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tions at which known drug resistance mutations were identified
resulted in a fully compatible tree.
Although the selective pressure in patient A, due to various
drug regimens and eventually leading to multidrug resistance,
might be an extreme case of selection in molecular evolution,
it had a remarkable impact on our inference. Natural selection,
even if confined to a few positions in the sampled gene frag-
ment, can provide sufficient counterweight to the remaining
phylogenetic information resulting in incorrect clustering. This
observation demands caution when the pol gene is used for
testing transmission hypotheses in forensic investigations (e.g.,
references 23 and 25). The presence of resistance mutations
does not necessarily invalidate analyses of the pol gene for
forensic purposes because the hypothesis test of epidemiolog-
ical relatedness still provided convincing results (Fig. 1). This
was also confirmed in the RT gene by using additional drug-
resistant control sequences (see the supplemental material).
However, it is highly recommended to assess the impact of sites
with resistance-associated mutations by removing them from
the alignment in a parallel analysis (12). As accessibility to
antiretroviral treatment will increase, the footprint of drug-
selective pressure might become a common feature in pol se-
quences. Reconstructions based on the env gp41 gene region,
known to be subject to host immune-selection pressure as
TABLE 3. Parameter estimates for the codon substitution models applied to the pol data
Model pa Log Ld Estimates of parametersb Positively selected sitesc
M0 (1 ratio) 1 2,137.255821 ˆ  0.3918 None
Branch specific (2 ratios) 2 2,129.700900 ˆ0  0.2495, ˆ1  1.6230 NA
Site-specific
M1, neutral (K  2) 1 2,118.947877 pˆ0  0.68985 (pˆ1  0.31015) Not allowed
M2, selection (K  3) 3 2,107.074525 pˆ0  0.67099, pˆ1  0.32597
(pˆ2  0.00304), ˆ2  52.92262
RT, 215 (P  99)
M3, discrete (K  2) 3 2,112.026513 pˆ0  0.93249, (pˆ1  0.06751)
0  0.17437, ˆ1  4.26134
Pro, 12, 54, 72 (at 0.5  P  0.95), 37
(at P  99)
RT, 41, 174, 177, 245 (at 0.5  P 
0.95), 36, 135, 184, 210, 211, 215 (at
P  99)
M3, discrete (K  3) 5 2,104.838467 pˆ0  0.89797, pˆ1  0.09907,
(pˆ2  0.00297)
PRO, 10, 12, 16, 18, 38, 72, 82, (at 0.5
 P  0.95), 37, 54, (at P  95)
ˆ0  0.14630, ˆ1  2.75117,
ˆ2  60.67074
RT, 41, 174, 177, 204 (at 0.5  P 
0.95), 210, 211, 215T, 245, 36, 135,
184 (at P  95)
M7, beta 2 2,118.943419 pˆ  0.04111, qˆ  0.11138 Not allowed
M8, beta &  4 2,112.028167 pˆ0  0.93293, pˆ  21.08181,
qˆ  99.00000 (pˆ1  0.06707),
ˆ  4.27569
Same as M3 (K  2)
Branch site
A 3 2,113.535572 pˆ0  0.64620, pˆ1  0.18545,
(pˆ2  pˆ3  0.16835)
2  4.73987
Sites for foreground: PRO, 10, 13, 33,
37, 38, 41, 48, 62, 82, 89 (at 0.5  P
 0.95), 54 (at P  95)
RT, 20, 44, 48, 67, 201, 208, 215, 219,
223 (at 0.5  P  0.95)
B 5 2,108.351559 pˆ0  0.77144, pˆ1  0.04723
(pˆ2  pˆ3  0.18132)
Sites for background: Pro, 12, 37 (at
0.5  P  0.95)
RT, 36, 41, 135, 174, 177, 184, 204,
210, 211, 215, 245 at (0.5  P 
0.95)
ˆ0  0.10933, ˆ1  4.34176,
ˆ2  2.91030
Sites for foreground: Pro, 10, 13, 33,
38, 41, 48, 54, 62, 72, 82, 89 (at 0.5
 P  0.95)
RT, 20, 44, 48, 67, 201, 208, 219, 223
(at 0.5  P  0.95)
a p is the number of free parameters for the  ratios.
b Parameters indicating positive selection are presented in bold type. Those in parentheses are presented for clarity only but are not free parameters.
c An asterisk indicates the site belonging to the class with pˆ2 and ˆ2 in model M3 (K  3). Underlined sites refer to positions associated with drug resistance. NA,
not applicable.
d Log L, log likelihood.
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reflected in a higher overall dN/dS, did not seem to be severely
influenced by parallel substitutions. On the contrary, the env
gp41 data had the power to reject the incompatible pol evolu-
tionary history. This showed that obtaining sequence data for
multiple HIV genome regions is not a redundant recommen-
dation in forensic investigations (18). It is interesting to note
that patient A is now successfully being treated with the fusion
inhibitor T20, which targets the HIV-1 gp41 transmembrane
glycoprotein (15). Therefore, future sampling of this patient
might indeed also reveal an effect of drug-selective pressure in
the env gp41 gene (32).
A common convention for detecting the action of positive
selection is the nonsynonymous/synonymous substitution rate
ratio, a ratio greater than 1 indicating that nonsynonymous
mutations offer fitness advantages and have a higher fixation
rate than synonymous mutations. Unfortunately, an average
ratio usually has little power to detect positive selection (e.g.,
references 1, 7, and 35). For the evolution of HIV drug resis-
tance in particular, Crandall et al. (4) have shown that this
ratio is a poor indicator of natural selection. This is not sur-
prising, since for the conventional drugs, resistance mutations
are fixed in the most functionally conserved protein of the HIV
genome. Using codon substitution models, we were able to
explicitly test differential selective pressure in patient A. Al-
though this approach confirmed a significantly higher dN/dS
along these lineages compared to the background, we still
could not demonstrate any positive selection in the patient A
lineages with statistical significance. Only the most complex
model for detecting molecular adaptation at individual sites
along specific lineages (branch site model B) revealed posi-
tively selected sites in patient A, in addition to positively se-
lected sites throughout the complete genealogy. Interestingly,
the latter included several positions with resistance mutations
identified in more than one patient, while the former included
several positions with resistance mutations exclusively seen in
patient A. An exception to this was position 44, for which a
drug resistance mutation was observed in both patient A and
patient B but was identified as a positively selected site only in
patient A. However, this mutation is only present as an allelic
mixture in the patient B population sequence and therefore
was not fully fixed in the population at that time of sampling.
It remains to be elucidated whether the remaining sites iden-
tified to be under positive selection are resistance associated,
selected by the host immune system or simply false positives.
For example, it is interesting to note that mutations at posi-
tions 20, 203, and 218 in the RT, identified as positively se-
lected in the foreground lineage, were significantly associated
with nucleoside RT inhibitor therapy in a recent comprehen-
sive statistical analysis (9).
Finally, we have demonstrated that the increased fixation of
resistance mutations in patient A resulted in a significantly
higher evolutionary rate along a terminal branch in patient A.
Again, this could be explicitly tested by maximum likelihood
modeling. However, the local molecular clock model with
dated tips was still significantly rejected in favor of the different
rates model, which does not assume a molecular clock. A
molecular clock in the env gp41 gene was also rejected. This
was in contrast with the Swedish transmission chain that sup-
ported the existence of a molecular clock (17). The difference
might have resulted from a different testing approach or from
the impact of antiretroviral treatment. On the one hand, it has
been shown that effective treatment can result in a slowing
down or even cessation of viral evolution (6). On the other
hand, suboptimal therapy can lead to drug resistance, which
can result in increased mutation rates, in turn increasing the
likelihood of further resistance under ongoing therapy (24).
The latter might have been the evolutionary pathway in patient
A.
In conclusion, we were able to uncover the molecular foot-
print of drug-selective pressure in a case where the HIV trans-
mission history was known. If the aim would have been to
estimate the transmission history, which is much more com-
mon in HIV phylogenetics, we would have drawn incorrect
conclusions on the basis of the pol gene region. Therefore, we
suggest that caution should be taken when accurate recon-
structions of HIV evolution are required.
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